Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

Pre-Market: $150.77 +1.01 (0.67%) 8:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Zai Lab Stock Down, Atopic Dermatitis Candidate Trial Fails

Shares of Zai Lab (ZLAB) decline following the failure of a phase IIA study on its pipeline candidate, ZL-3101, for the treatment of atopic dermatitis.

    5 Momentum Stocks Worth Investing in via Driehaus Strategy

    Using the "buy high and sell higher" rule, Richard Herman Driehaus has created an investment approach.

      Nalak Das headshot

      Indexes Close at Record High as Markets Move North: 5 Picks

      As a result of markets' northbound movement, two major indexes ??? S&P 500 and Nasdaq Composite ??? closed at an all-time high on Aug 24.

        Here's Why You Should Invest in Integer (ITGR) Stock Now

        Integer Holdings (ITGR) gains on strong quarterly performance. The company is likely to gain from the Cardio & Vascular, Neuromodulation and Non-Medical Electrochem markets.

          Veeva Systems (VEEV) Q2 Earnings & Revenues Beat Estimates

          Veeva Systems (VEEV) gains from its flagship Vault platform. Also, expanding margins are an added positive for the company.

            AbbVie Posts Positive Data on Elagolix for Uterine Fibroids

            AbbVie (ABBV) reports positive top-line results from a phase III extension trial on its investigational candidate Elagolix for treating uterine fibroids in women.

              Exact Sciences Inks Cologuard Co-Promotion Deal With Pfizer

              Exact Sciences (EXAS) reaches a co-promotion agreement with Pfizer to commercialize its non-invasive screening test for colorectal cancer, Cologuard. The stock rallies following this news.

                Here's Why You Should Invest in Illumina (ILMN) Stock Now

                Illumina (ILMN) gains on strategic partnerships and international prospects.

                  Pacira (PCRX) Rides High on Robust Exparel Performance

                  Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

                    Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

                    Is (ILMN) Outperforming Other Medical Stocks This Year?

                      Swarup Gupta headshot

                      Bull Market Set to Become Longest in History: 5 Picks

                      The strength of the economy and the success of U.S. tech majors indicates that the rally isn't going to run out of steam.

                        Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q4

                        Myriad Genetics (MYGN) witnesses strong performances from GeneSight, EndoPredict, Vectra DA and Prolaris tests in Q4.

                          Alexion's BLA for ALXN1210 Gets Priority Review From FDA

                          The FDA grants priority review to Alexion's (ALXN) BLA for its C5 complement inhibitor ALXN1210 with respect to the treatment of patients with paroxysmal nocturnal hemoglobinuria.

                            Medtronic (MDT) Q1 Earnings Beat on Growth in All Lines

                            All major business groups of Medtronic (MDT) contribute to solid top-line growth at CER, which highlighted sustainability across groups and regions.

                              Roche's Lung Cancer Drug Alecensa Gets Approval in China

                              The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.

                                Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

                                Sector ETF report for ARKG

                                  Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

                                  Zacks.com highlights: Illumina, Vertex Pharmaceuticals, Surmodics and McDermott International

                                    Tirthankar Chakraborty headshot

                                    4 Winning Stocks With Solid Efficiency Level

                                    A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.

                                      Evoke Pharma (EVOK) Announces FDA Acceptance of Gimoti NDA

                                      The FDA accepts Evoke Pharma's (EVOK) regulatory application seeking approval of its pipeline candidate, Gimoti, for treating diabetic gastroparesis. Shares up.

                                        Accuray (ARAY) Earnings Beat in Q4, Gross Orders Rise Y/Y

                                        Accuray's (ARAY) flagship Radixact System drives Q4 results; overseas gains raise hope.

                                          Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

                                          Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

                                            Can Illumina (ILMN) Stock Continue to Grow Earnings?

                                            Illumina (ILMN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

                                              Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

                                              Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

                                                Corcept (CORT) Earnings and Revenues Miss Estimates in Q2

                                                Corcept's (CORT) earnings and revenues lag estimates in Q2. Meanwhile, the company posts positive interim data from phase I/II study on its pipeline candidate relacorilant.

                                                  Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales

                                                  Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.